Shares of Melinta Therapeutics, Inc. (NASDAQ:MLNT) have earned a consensus recommendation of “Hold” from the ten analysts that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $13.00.
Several research analysts have recently issued reports on the stock. ValuEngine upgraded shares of Melinta Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 2nd. Zacks Investment Research cut shares of Melinta Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, September 13th. Jefferies Financial Group assumed coverage on shares of Melinta Therapeutics in a report on Tuesday, September 11th. They issued a “buy” rating and a $15.00 price target on the stock. Cantor Fitzgerald set a $15.00 price target on shares of Melinta Therapeutics and gave the company a “buy” rating in a report on Tuesday, September 18th. Finally, HC Wainwright assumed coverage on shares of Melinta Therapeutics in a report on Tuesday, September 11th. They issued a “buy” rating and a $14.00 price target on the stock.
Shares of Melinta Therapeutics stock opened at $4.15 on Wednesday. The company has a current ratio of 1.97, a quick ratio of 1.65 and a debt-to-equity ratio of 0.41. Melinta Therapeutics has a 52-week low of $3.95 and a 52-week high of $18.20. The company has a market capitalization of $252.04 million, a PE ratio of -0.19 and a beta of 1.16.
Large investors have recently added to or reduced their stakes in the stock. Granahan Investment Management Inc. MA bought a new stake in Melinta Therapeutics in the second quarter valued at $1,932,000. Stonepine Capital Management LLC bought a new stake in Melinta Therapeutics in the second quarter valued at $331,000. Schwab Charles Investment Management Inc. boosted its holdings in Melinta Therapeutics by 56.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 74,668 shares of the biotechnology company’s stock valued at $553,000 after acquiring an additional 27,047 shares in the last quarter. BlackRock Inc. boosted its holdings in Melinta Therapeutics by 41.8% in the first quarter. BlackRock Inc. now owns 857,398 shares of the biotechnology company’s stock valued at $6,344,000 after acquiring an additional 252,943 shares in the last quarter. Finally, Laurion Capital Management LP bought a new stake in Melinta Therapeutics in the second quarter valued at $631,000. Institutional investors and hedge funds own 68.60% of the company’s stock.
Melinta Therapeutics Company Profile
Melinta Therapeutics, Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, an antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Vabomere, a carbapenem used in treatment of gram-negative infections; Orbactiv, an antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens, as well as Solithromycin, a macrolide antibiotic for the treatment of CABP.
Recommended Story: How is the S&P 500 index different from the DJIA?
Receive News & Ratings for Melinta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Melinta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.